Technical Report Medical Education Osteopathic Medicine
Rethinking ventilator-free days in patients on haemodialysis: the role of low-dose aspirin

Rethinking ventilator-free days in patients on haemodialysis: the role of low-dose aspirin

Authors

Hugo Osei

Hugo Osei

Hamad Medical Corporation, Eritrea

Zainab Kim

Zainab Kim

Mayo Clinic, North Macedonia

Corresponding
Felix Nasser

Felix Nasser

Cleveland Clinic Abu Dhabi, Bonaire, Sint Eustatius and Saba

Mei Costa

Mei Costa

Royal Melbourne Hospital, Niue

Aisha Kaur

Aisha Kaur

Hamad Medical Corporation, Czech Republic

Felix Moreau

Felix Moreau

St Thomas' Hospital, Northern Mariana Islands

Published

September 8, 2026

Paper ID

PAP-000226

Status

Published

DOI

10.65712/tmj.test000484

Rethinking ventilator-free days in patients on haemodialysis: the role of low-dose aspirin

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Practice around low-dose aspirin varies widely between centres. Methods: Eligible participants were patients on haemodialysis. Results: ventilator-free days occurred in 12% of the intervention group versus 13% of controls. ventilator-free days occurred in 15% of the intervention group versus 15% of controls. Conclusion: Future work should test low-dose aspirin in a pragmatic multicentre trial.

Introduction

Guidelines make only a weak recommendation on low-dose aspirin. Practice around low-dose aspirin varies widely between centres. The cost of ventilator-free days to health systems is substantial.

Guidelines make only a weak recommendation on low-dose aspirin. ventilator-free days remains a leading cause of avoidable harm among patients on haemodialysis.

Discussion

Future work should test low-dose aspirin in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols. These findings suggest that low-dose aspirin is associated with better ventilator-free days in patients on haemodialysis.

These findings suggest that low-dose aspirin is associated with better ventilator-free days in patients on haemodialysis. Implementation will depend on staffing, cost and local protocols.

These findings suggest that low-dose aspirin is associated with better ventilator-free days in patients on haemodialysis.

Implementation will depend on staffing, cost and local protocols. Future work should test low-dose aspirin in a pragmatic multicentre trial.

Conclusions

Low-dose aspirin should be considered for patients on haemodialysis to improve ventilator-free days.

References

1. Zhang L, Patel H, et al. Pharmacist-led medication review and falls. N Engl J Med. 2023;38(7):478-1736.

2. Tanaka F, Lindqvist X, et al. Prone positioning and patient satisfaction. BMJ. 2018;260(1):110-915.

3. Farouk F, Silva C, et al. Tranexamic acid and ventilator-free days. Crit Care Med. 2008;141(5):105-1486.

4. Moreau Y, Volkov J, et al. Early mobilisation and emergency department revisits. JAMA. 2014;26(10):684-1790.

5. Nakamura Q, Mensah P, et al. Frailty screening and surgical site infection. N Engl J Med. 2014;105(7):523-1671.

6. Schmidt J, Tanaka D, et al. Delayed cord clamping and surgical site infection. Pediatrics. 2019;248(7):490-1414.

7. Costa R, Novak I, et al. Machine-learning triage and 30-day readmission. Lancet. 2022;124(3):581-1380.

8. Kowalski E, Patel Y, et al. An antibiotic stewardship programme and surgical site infection. Crit Care Med. 2019;352(6):505-1644.

Appendices

Ethics approval: IRB-6316.

Materials and Methods

We conducted a case series across 11 centres between 2015 and 2022. Eligible participants were patients on haemodialysis.

Analyses were adjusted for age, sex and baseline severity.

Results

Serious adverse events were rare and similar between groups. 541 participants were included (median age 41 years). Effects were consistent across prespecified subgroups. 3318 participants were included (median age 42 years).

1283 participants were included (median age 82 years). 1108 participants were included (median age 57 years). ventilator-free days occurred in 12% of the intervention group versus 26% of controls. 4205 participants were included (median age 42 years).

GroupnEvents
Centre B89887
Male60629
Age ≥ 6561290
Control71051
TABLE 1: Secondary outcomes
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Trend in ventilator-free days
Shown for patients on haemodialysis; error bars are 95% confidence intervals.

4085 participants were included (median age 36 years). Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.45 (95% CI 0.36 to 0.96).

The adjusted odds ratio was 0.42 (95% CI 0.48 to 0.80). Serious adverse events were rare and similar between groups.